Nothing Special   »   [go: up one dir, main page]

PL1926476T3 - Amorficzne stałe dyspersje 7-chloro-N,N,5-trimetylo-4-okso-3-fenylo-3,5-dihydro-4H-pirydazyno[4,5-b]indolo-1-acetamidu - Google Patents

Amorficzne stałe dyspersje 7-chloro-N,N,5-trimetylo-4-okso-3-fenylo-3,5-dihydro-4H-pirydazyno[4,5-b]indolo-1-acetamidu

Info

Publication number
PL1926476T3
PL1926476T3 PL06802215T PL06802215T PL1926476T3 PL 1926476 T3 PL1926476 T3 PL 1926476T3 PL 06802215 T PL06802215 T PL 06802215T PL 06802215 T PL06802215 T PL 06802215T PL 1926476 T3 PL1926476 T3 PL 1926476T3
Authority
PL
Poland
Prior art keywords
pyridazino
acetamide
indole
dihydro
trimethyl
Prior art date
Application number
PL06802215T
Other languages
English (en)
Inventor
Irwin C Jacobs
John D Higgins
Micael Guillot
Nancy M Franson
William L Rocco
Khawla Abdullah Abu-Izza
Original Assignee
Sanofi Aventis Us Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37499538&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1926476(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis Us Llc filed Critical Sanofi Aventis Us Llc
Publication of PL1926476T3 publication Critical patent/PL1926476T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/5025Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
PL06802215T 2005-08-29 2006-08-24 Amorficzne stałe dyspersje 7-chloro-N,N,5-trimetylo-4-okso-3-fenylo-3,5-dihydro-4H-pirydazyno[4,5-b]indolo-1-acetamidu PL1926476T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US71215005P 2005-08-29 2005-08-29
EP06802215.1A EP1926476B1 (en) 2005-08-29 2006-08-24 Amorphous solid dispersions of 7-chloro-n,n,5-trimethyl-4-oxo-3-phenyl-3,5,-dihydro-4h-pyridazino[4,5-b]indole-1-acetamide
PCT/US2006/033022 WO2007027494A2 (en) 2005-08-29 2006-08-24 Morphous solid dispersions of 7-chloro-n,n, 5-trimethyl-4-oxo-3-phenyl-3, 5,-dihydro-4h-pyridazino [4, 5-b] indole-1-acetamide

Publications (1)

Publication Number Publication Date
PL1926476T3 true PL1926476T3 (pl) 2013-08-30

Family

ID=37499538

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06802215T PL1926476T3 (pl) 2005-08-29 2006-08-24 Amorficzne stałe dyspersje 7-chloro-N,N,5-trimetylo-4-okso-3-fenylo-3,5-dihydro-4H-pirydazyno[4,5-b]indolo-1-acetamidu

Country Status (31)

Country Link
US (1) US7713548B2 (pl)
EP (1) EP1926476B1 (pl)
JP (1) JP5026426B2 (pl)
KR (1) KR20080061354A (pl)
CN (1) CN101272767B (pl)
AR (1) AR055615A1 (pl)
AU (1) AU2006285111B8 (pl)
BR (1) BRPI0615609A2 (pl)
CA (1) CA2619438A1 (pl)
CR (1) CR9750A (pl)
DK (1) DK1926476T3 (pl)
EA (1) EA015715B1 (pl)
EC (1) ECSP088203A (pl)
ES (1) ES2414434T3 (pl)
HK (1) HK1124785A1 (pl)
HN (1) HN2008000360A (pl)
HR (1) HRP20130533T1 (pl)
IL (1) IL189587A (pl)
MA (1) MA29783B1 (pl)
ME (1) ME01560B (pl)
NO (1) NO20081364L (pl)
NZ (1) NZ566313A (pl)
PL (1) PL1926476T3 (pl)
PT (1) PT1926476E (pl)
RS (1) RS52914B (pl)
SI (1) SI1926476T1 (pl)
TN (1) TNSN08069A1 (pl)
TW (1) TWI398250B (pl)
UA (1) UA93517C2 (pl)
WO (1) WO2007027494A2 (pl)
ZA (1) ZA200801893B (pl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3091011T (lt) 2006-04-07 2018-04-10 Vertex Pharmaceuticals Incorporated Atp surišančios kasetės transporterių moduliatoriai
EP2155166A2 (en) * 2007-05-11 2010-02-24 F. Hoffmann-Roche AG Pharmaceutical compositions for poorly soluble drugs
MX2010009344A (es) * 2008-03-11 2012-09-28 Reddys Lab Ltd Dr Preparacion de lenalidomida.
AU2009283039A1 (en) * 2008-08-18 2010-02-25 Sanofi-Aventis U.S. Llc Process for preparing polymorph of 7-chloro-N, N,5-trimethyl-4-oxo-3-phenyl-3,5-dihydr0-4H-pyridazin0[4,5-b]indole-1-acetamide
WO2011119984A1 (en) * 2010-03-25 2011-09-29 Vertex Pharmaceuticals Incorporated Solid forms of (r)-1(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihyderoxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
EP2822539B1 (en) 2012-03-07 2018-11-21 National Institute Of Pharmaceutical Education And Research (NIPER) Nanocrystalline solid dispersion compositions
KR101986683B1 (ko) * 2012-12-13 2019-06-10 한미약품 주식회사 테트라졸 유도체를 활성 성분으로 포함하는 용해도가 개선된 고체 분산체
WO2015030788A1 (en) * 2013-08-30 2015-03-05 Hewlett-Packard Development Company, L.P. Comparing real-time movements to pattern profile background
EP3120871B1 (en) * 2014-03-18 2023-06-28 Takeda Pharmaceutical Company Limited Solid dispersion
SI3925607T1 (sl) 2014-04-15 2023-10-30 Vertex Pharmaceuticals Incorporated Farmacevtski sestavki za zdravljenje bolezni, ki jih povzroča regulator transmembranske prevodnosti pri cistični fibrozi
US10246461B2 (en) 2016-02-29 2019-04-02 Genentech, Inc. Dosage form compositions comprising an inhibitor of bruton's tyrosine kinase
CA3066046A1 (en) * 2017-07-04 2019-01-10 Jiangsu Hengrui Medicine Co., Ltd. Pharmaceutical composition and method for preparing same

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5091381A (en) * 1991-04-12 1992-02-25 Biomeasure, Inc. 2H-1,3,4-benzotriazepin-2-ones
TW487582B (en) * 1995-08-11 2002-05-21 Nissan Chemical Ind Ltd Method for converting sparingly water-soluble medical substance to amorphous state
FR2766823B1 (fr) * 1997-07-30 1999-10-08 Synthelabo Derives de 4-oxo-3,5-dihydro-4h-pyridazino[4,5-b] indole-1-acetamide, leur preparation et leur application en therapeutique
DE69837903T2 (de) * 1997-08-11 2008-02-14 Pfizer Products Inc., Groton Feste pharmazeutische Dispersionen mit erhöhter Bioverfügbarkeit
AUPP278498A0 (en) * 1998-04-03 1998-04-30 Australian Nuclear Science & Technology Organisation Peripheral benzodiazepine receptor binding agents
FR2788696B1 (fr) * 1999-01-26 2004-03-05 Synthelabo Utilisation de derives de pyridazino [4,5-b] indole-1-acetamide pour la preparation de medicaments destines aux maladies du systeme nerveux central
DE60039377D1 (de) * 1999-02-09 2008-08-21 Pfizer Prod Inc Zusammensetzungen basischer Arzneistoffe mit verbesserter Bioverfügbarkeit
EP1027886B1 (en) * 1999-02-10 2008-07-09 Pfizer Products Inc. Pharmaceutical solid dispersions
EP1027887B1 (en) * 1999-02-10 2008-08-13 Pfizer Products Inc. Matrix controlled release device
EP1120109A3 (en) * 2000-01-24 2002-07-10 Pfizer Products Inc. Rapidly disintegrating and fast dissolving solid dosage form
FR2829939B3 (fr) * 2001-09-21 2003-11-28 Sanofi Synthelabo Utilisation du 7-chloro-n,n,5-trimethyl-4-oxo-3-phenyl-3,5- dihydro-4h-pyridazino(4,5-b)indole-1-acetamide pour la preparation de medicaments destines au traitement de la polyarthrite rhumatoide
CL2004001884A1 (es) * 2003-08-04 2005-06-03 Pfizer Prod Inc Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
US20050220881A1 (en) * 2003-10-10 2005-10-06 Bvm Holding Co. Pharmaceutical composition

Also Published As

Publication number Publication date
TWI398250B (zh) 2013-06-11
ECSP088203A (es) 2008-06-30
EP1926476A2 (en) 2008-06-04
PT1926476E (pt) 2013-07-10
WO2007027494A3 (en) 2007-08-02
AU2006285111A1 (en) 2007-03-08
WO2007027494A2 (en) 2007-03-08
CN101272767B (zh) 2012-08-29
HK1124785A1 (pl) 2009-07-24
MA29783B1 (fr) 2008-09-01
HN2008000360A (es) 2011-05-31
RS52914B (en) 2014-02-28
AU2006285111B8 (en) 2012-05-17
ES2414434T3 (es) 2013-07-19
ZA200801893B (en) 2009-08-26
SI1926476T1 (sl) 2013-07-31
EP1926476B1 (en) 2013-04-10
TNSN08069A1 (en) 2009-07-14
AU2006285111B2 (en) 2012-04-26
JP5026426B2 (ja) 2012-09-12
UA93517C2 (en) 2011-02-25
IL189587A0 (en) 2008-08-07
AR055615A1 (es) 2007-08-29
US20080160080A1 (en) 2008-07-03
HRP20130533T1 (en) 2013-07-31
EA200800713A1 (ru) 2008-10-30
JP2009506114A (ja) 2009-02-12
NZ566313A (en) 2011-04-29
CA2619438A1 (en) 2007-03-08
KR20080061354A (ko) 2008-07-02
CR9750A (es) 2008-06-18
US7713548B2 (en) 2010-05-11
CN101272767A (zh) 2008-09-24
IL189587A (en) 2012-12-31
NO20081364L (no) 2008-04-03
EA015715B1 (ru) 2011-10-31
DK1926476T3 (da) 2013-07-01
BRPI0615609A2 (pt) 2011-05-24
TW200727902A (en) 2007-08-01
ME01560B (me) 2014-04-20

Similar Documents

Publication Publication Date Title
HRP20130533T1 (en) Amorphous solid dispersions of 7-chloro-n,n, 5-trimethyl-4-oxo-3-phenyl-3, 5,-dihydro-4h-pyridazino[4,5-b]indole-1-acetamide
IL186881A0 (en) Pyrido [2, 3 - d] pyrimidines useful as hcv inhibitors, and methods for the preparation thereof
EP2223921B8 (en) 2-Thiophen-2-yl-oxazole, 2-Thiophen-2-yl-thiazole and 2-Thiophen-2-yl-1H-imidazole derivatives as antiviral agents
HK1118556A1 (en) 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives
IL192236A0 (en) Aryl-isoxazol-4-yl-imidazo[1,5-a]pyridine derivatives
ZA200809796B (en) Pyrazolo [1,5-A]pyrimidines as CDK inhibitors
ZA200906736B (en) New 3-([1,2,4] Triazolo [4,3-A]Pyridin-7-YL) Benzamide derivatives
IL206466A0 (en) PYRAZOLO [1,5-a]PYRIMIDINES, COMPOSITIONS COMPRISING THE SAME AND USES THEREOF
IL198239A0 (en) Substituted 8-piperidinyl-2-pyridinyl-pyrimido [1,2-a] pyrimidin -6- one and 8-piperidinyl-2- pyrimidinyl [1,2-a] pyrimidin -6- one derivatives
BRPI0822239A2 (pt) Composto de pirazolo[1,5-a] pirimidina
HK1120803A1 (en) Pyrazolo
IL189181A0 (en) Novel 4-amino-thieno[3,2-c]pyridine-7-
IL191568A0 (en) Novel process for the preparation of 5-amino-3h-thiazolo[4,5-d]pyrimidin-2-one
IL187441A0 (en) Derivatives of 6,7-dihydro-5h-imidazo[1,2-a] imidazole-3-sulfonic acid
PL2059521T3 (pl) Pirazolo[1,5-A]pirymidyny,sposoby, zastosowanie i kompozycje
GB0710111D0 (en) Pyrrolo [2, 1-C] [1, 4] benzodiazepine-anthraquinone conjugates useful as antitumour agents
PL375287A1 (pl) Nowa pochodna izoksazolo[4,5-d]pirymidyny i sposób wytwarzania nowej pochodnej izoksazolo[4,5-d]pirymidyny
AU2005902215A0 (en) Improved pelvic brace
AU2005903166A0 (en) "Seat Safe"
AU2005900789A0 (en) Aminoalcohol Derivatives
PL373355A1 (pl) Nowe 8-podstawione-3-imino-2,3,7,8-tetrahydro-imidazo [2,1-c][1,2,4]triazyno-4(6H)-ony i sposób ich otrzymywania
AU2005901180A0 (en) Patent For The Fountain of youth
AU2005903065A0 (en) Challenge based boardgame
AU2005901194A0 (en) Super morgages
AU2005904248A0 (en) Super Lagg